Sigma Genetics GTM brain

Sigma Genetics develops magnetic-field-based intracellular delivery technology and is pursuing cell and gene therapy applications.

market profile

text: Cell therapy developers need delivery approaches that can be evaluated for cell viability, payload delivery and manufacturing scalability.
text: Sigma's platform and therapeutic programs are described by external sources, but current commercial availability and comparative clinical evidence remain unclear.

title: Cell therapy process development director
pains:
- Needs a delivery process compatible with viable cell recovery and eventual manufacturing scale
- Must compare new methods with established transfection workflows for the specific cell product
title: Gene delivery research scientist
pains:
- Must test whether a platform works for their particular cells and payloads
- Needs reproducible evidence before changing an established experimental workflow
title: Biopharma partnership lead
pains:
- Needs to assess intellectual property, development maturity and partnership rights
- Must distinguish exploratory platform claims from evidence relevant to a program

text: Cell and gene therapy developers and academic groups studying intracellular delivery or engineered cellular products; account size and commercial eligibility are unconfirmed.
text: Biopharma teams exploring scalable cell engineering and potential co-development partnerships, subject to technical and commercial validation.

objection: Does it improve outcomes over our existing delivery method?
response: Request comparative evidence for the relevant cell type, payload and desired endpoint before making claims of superiority.
objection: Is the technology available for a regulated manufacturing workflow?
response: Ask about access, validation, quality requirements and manufacturing readiness; public information does not establish these.
objection: Is this a platform partnership or a therapeutic product purchase?
response: Confirm the current business model, partnership scope and IP terms directly with Sigma.

name: CellFE
why: Alternative intracellular delivery technology for cell engineering and therapy development.
name: Indee Labs
why: Develops nonviral cell engineering delivery, overlapping the process-development use case.

name: Zachary Rapp
url: https://ctmct.ucsf.edu/content/innovation-commercialization-council
why: UCSF identifies him as CEO and co-founder discussing Sigma's gene delivery work and partnerships.

text: A cell therapy group is evaluating new delivery methods as it develops an engineered cell product.
text: A research organization is seeking a development partner for delivery of genetic payloads into cells.

model: unknown

unknown

low

name: Karen Eaton
title: Founder/CEO
role: CEO
bio: Highly motivated to advance the healthcare field and I aspire to use both my business skills and scientific background to forward the medical industry. Interested in all things bio: cell/gene therapy, computational enzyme design, immunology, diagnostics, health devices, and so much more.
name: Matthew Scholz
title: Founder
role: Founder
bio: Matthew is a serial entrepreneur with a background in gene therapy and computer security. He has founded or co-founded five biotechnology companies and has played an integral role in the development of several advanced therapeutics, including three first-in-class treatment modalities. He is the author of dozens of patents covering innovations ranging from novel transfection technologies, immune cell programming, in vivo production of therapeutic proteins, senolytics, longevity, and oncology.
name: Chris Pihl
title: Founder
role: Founder